Guardant Health (GH) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.42
- Estimate
- -$0.39
- Surprise
- -7.8%
- Revenue (period 2026-06-30)
- $335.0M
- Score at report (before → after)
- 5.3 → 5.6/10
Revenue source: xbrl.
How the report landed
Guardant Health (GH) reported a wider loss than forecast — diluted EPS of -$0.42 against the -$0.39 estimate (a 7.8% shortfall). TrendMatrix's engine moved from Data Issue (5.3/10) to Hold at 5.6/10 after the report — the engine's score rose despite the miss.
Where TrendMatrix's rating stands now
TrendMatrix currently rates GH Sell at 5.5/10.
2 of the last 4 quarters beat the estimate; this quarter's -7.8% surprise compares with a +2.7% four-quarter average. Next scheduled report: 2026-10-28.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong growth profile
What argues against it
- Concentration risk — Product: tests (94.0%)
- Analyst target reached - limited upside remaining
- Near 52-week high (2.5% away)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $175.00
- Price target
- $176.23
- Stop
- $162.66
- Upside to target
- +0.7%
- Reward-to-risk
- 0.1:1
Model outputs from TrendMatrix’s engine as of 2026-09-17 — shown for context, not personalized investment advice.
GH at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Diagnostics & Research
- Market cap
- $23.57B
- P/E (fwd)
- -441.3
- 52-week range
- $55.38–$179.30
- Off 52-week high
- 2.4%
- RSI (14)
- 54
- Volume vs avg
- 0.85×
- Score today
- 5.5/10